We are an infection treatment and control solutions company that has created two significant broad spectrum (non-antibiotic based) chemistries to combat viral, bacterial, fungal and mold caused infection in wounds, surgical sites, eyes, body cavities and in the lung without causing antibiotic resistance. Our platform technologies have the potential to significantly reduce the $30 billion spent in the US each year on antibiotic resistant infections and over $80 billion per year on the various influenza flu’s. Our platforms may replace antiquated chemistries and therapies used on over 2 million bacterial infections and on over 40 million influenza cases resulting in more than 100,000 patient deaths each year in just the United States.